If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

Growth stocks are routinely some of the market’s hottest stocks, and it’s not unusual to have the market’s top performers ...

瑞士楚格和波士顿 - 目前股价为$39.69，市值33.9亿美元的CRISPR Therapeutics (NASDAQ:CRSP)宣布了其2025年战略重点，专注于继续推出其基因药物CASGEVY®以及几个关键开发项目的更新。公司以强劲的资产负债表开始新的一年，拥有约19亿美元的现金、现金等价物和可销售证券。根据 InvestingPro ...

Unlike the Dow, the S&P 500 GARP Index selects 75 stocks from the broader S&P 500 based on "growth scores" and "composite scores" for quality and value. Growth scores rely on metr ...

在生物科技公司面临挑战的一年里，CRISPR Therapeutics AG的股票在更广泛的市场下跌中跌至52周低点，触及38.2美元。根据 InvestingPro 的数据，该公司保持"良好"的整体财务健康评分，其资产负债表显示现金多于债务，表现尤为强劲。这家以基因编辑开创性工作而闻名的公司，过去一年股价大幅回落38.23%。这一下跌反映了投资者对监管障碍、临床试验进度以及基因编辑疗法盈利能力的 ...

India News Live: Stay informed with our live blog covering India’s latest in politics, economy, crime, and general news. Get real-time updates on political developments, financial trends, crime ...